When a new drug enters the market, it brings with it both hope and uncertainty. Clinical trials, despite their scientific rigor, are limited in scope — they can’t predict how a drug will behave in real-world conditions, across varied patient…
Recent Post
- India brings Pregabalin under Schedule H1
- CDSCO Issues Stern Warning Against Injectable Cosmetics and Misleading Beauty Claims
- CDSCO Orders Nationwide Crackdown on Unauthorised GLP-1 Weight Loss Drugs
- Drug Applications with Unanswered Queries to Be Rejected Within 30 Days by CDSCO
- ⚖️ “No Approval, No Market”: Delhi High Court Sends a Strong Message on Unapproved Drugs & FDCs
